KR870002107A - 신규 화합물, 그 제조 방법 및 이 화합물을 함유하는 조성물 - Google Patents
신규 화합물, 그 제조 방법 및 이 화합물을 함유하는 조성물 Download PDFInfo
- Publication number
- KR870002107A KR870002107A KR1019860007234A KR860007234A KR870002107A KR 870002107 A KR870002107 A KR 870002107A KR 1019860007234 A KR1019860007234 A KR 1019860007234A KR 860007234 A KR860007234 A KR 860007234A KR 870002107 A KR870002107 A KR 870002107A
- Authority
- KR
- South Korea
- Prior art keywords
- dihydro
- thiadiazole
- carboxylic acid
- alanyl
- phenylpropyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 22
- 239000000203 mixture Substances 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 14
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 150000001408 amides Chemical class 0.000 claims 7
- 150000002148 esters Chemical class 0.000 claims 7
- -1 NR 4 R 5 Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 125000003884 phenylalkyl group Chemical group 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 3
- HYMXBWATPVGMLE-LNLFQRSKSA-N (2s)-3-[(2s)-6-amino-2-[[(1s)-1-carboxy-3-phenylpropyl]amino]hexanoyl]-5-tert-butyl-2h-1,3,4-thiadiazole-2-carboxylic acid Chemical compound OC(=O)[C@@H]1SC(C(C)(C)C)=NN1C(=O)[C@H](CCCCN)N[C@H](C(O)=O)CCC1=CC=CC=C1 HYMXBWATPVGMLE-LNLFQRSKSA-N 0.000 claims 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 150000001735 carboxylic acids Chemical class 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000002825 nitriles Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- UPTMCMOFMGLVSF-GRWTVWFQSA-N (2s)-3-[(2s)-2-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-5-(4-methylsulfanylphenyl)-2h-1,3,4-thiadiazole-2-carboxylic acid Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](SC(=N1)C=1C=CC(SC)=CC=1)C(O)=O)CC1=CC=CC=C1 UPTMCMOFMGLVSF-GRWTVWFQSA-N 0.000 claims 1
- UVUQJLHKAKUYHI-BPXKWBHBSA-N (2s)-3-[(2s)-2-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-5-phenyl-2h-1,3,4-thiadiazole-2-carboxylic acid Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](SC(=N1)C=1C=CC=CC=1)C(O)=O)CC1=CC=CC=C1 UVUQJLHKAKUYHI-BPXKWBHBSA-N 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- DERHNSJVDWFDKZ-UHFFFAOYSA-N 1,3,4-thiadiazole-2-carboxylic acid Chemical compound OC(=O)C1=NN=CS1 DERHNSJVDWFDKZ-UHFFFAOYSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000003491 array Methods 0.000 claims 1
- ULCJUHCUYPHITD-UHFFFAOYSA-N benzyl 1-(3-acetylsulfanylpropanoyl)-4-methyl-3-phenyl-5,6-dihydro-1,2,4-triazine-6-carboxylate Chemical compound CN1CC(C(=O)OCC=2C=CC=CC=2)N(C(=O)CCSC(C)=O)N=C1C1=CC=CC=C1 ULCJUHCUYPHITD-UHFFFAOYSA-N 0.000 claims 1
- CKQDUYZAOJHEMB-UHFFFAOYSA-N benzyl 3-(3-acetylsulfanylpropanoyl)-5-(2-phenylethyl)-2h-1,3,4-thiadiazole-2-carboxylate Chemical compound S1C(C(=O)OCC=2C=CC=CC=2)N(C(=O)CCSC(=O)C)N=C1CCC1=CC=CC=C1 CKQDUYZAOJHEMB-UHFFFAOYSA-N 0.000 claims 1
- HCUOJJRSVRNZJP-UHFFFAOYSA-N benzyl 3-(3-acetylsulfanylpropanoyl)-5-benzyl-2h-1,3,4-thiadiazole-2-carboxylate Chemical compound S1C(C(=O)OCC=2C=CC=CC=2)N(C(=O)CCSC(=O)C)N=C1CC1=CC=CC=C1 HCUOJJRSVRNZJP-UHFFFAOYSA-N 0.000 claims 1
- RDOODWZAYLCSCT-RBFZIWAESA-N benzyl 3-[(2s)-3-acetylsulfanyl-2-methylpropanoyl]-5-phenyl-2h-1,3,4-thiadiazole-2-carboxylate Chemical compound CC(=O)SC[C@@H](C)C(=O)N1N=C(C=2C=CC=CC=2)SC1C(=O)OCC1=CC=CC=C1 RDOODWZAYLCSCT-RBFZIWAESA-N 0.000 claims 1
- JXHIVXAMPXUCER-UHFFFAOYSA-N benzyl 4-(3-acetylsulfanylpropanoyl)-2-cyclohexyl-5,6-dihydro-1,3,4-thiadiazine-5-carboxylate Chemical compound CC(=O)SCCC(=O)N1N=C(C2CCCCC2)SCC1C(=O)OCC1=CC=CC=C1 JXHIVXAMPXUCER-UHFFFAOYSA-N 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- 125000002843 carboxylic acid group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- BKBBCUYUIQTREV-UHFFFAOYSA-N ethyl 3-(3-acetylsulfanylpropanoyl)-5-(4-chlorophenyl)-2h-1,3,4-thiadiazole-2-carboxylate Chemical compound CC(=O)SCCC(=O)N1C(C(=O)OCC)SC(C=2C=CC(Cl)=CC=2)=N1 BKBBCUYUIQTREV-UHFFFAOYSA-N 0.000 claims 1
- YSVRYNPQOSAQAM-UHFFFAOYSA-N ethyl 3-(3-acetylsulfanylpropanoyl)-5-(methylamino)-2h-1,3,4-thiadiazole-2-carboxylate Chemical compound CCOC(=O)C1SC(NC)=NN1C(=O)CCSC(C)=O YSVRYNPQOSAQAM-UHFFFAOYSA-N 0.000 claims 1
- LSIHLHWIFDWSAB-UHFFFAOYSA-N ethyl 3-(3-acetylsulfanylpropanoyl)-5-naphthalen-2-yl-2h-1,3,4-thiadiazole-2-carboxylate Chemical compound CC(=O)SCCC(=O)N1C(C(=O)OCC)SC(C=2C=C3C=CC=CC3=CC=2)=N1 LSIHLHWIFDWSAB-UHFFFAOYSA-N 0.000 claims 1
- PHVPKWCRPZHMOU-UHFFFAOYSA-N ethyl 3-(3-acetylsulfanylpropanoyl)-5-phenyl-2h-1,3,4-oxadiazole-2-carboxylate Chemical compound CC(=O)SCCC(=O)N1C(C(=O)OCC)OC(C=2C=CC=CC=2)=N1 PHVPKWCRPZHMOU-UHFFFAOYSA-N 0.000 claims 1
- HYCWSXSCWVUMDW-UHFFFAOYSA-N ethyl 3-(3-acetylsulfanylpropanoyl)-5-phenyl-2h-1,3,4-thiadiazole-2-carboxylate Chemical compound CC(=O)SCCC(=O)N1C(C(=O)OCC)SC(C=2C=CC=CC=2)=N1 HYCWSXSCWVUMDW-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
- C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Oscillators With Electromechanical Resonators (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (11)
- 일반식(I)의 화합물 및 제약상 허용되는 그의 염, 에스테르 및 아미드.상기 식중 Y는 S, O, 또는 NR9이고,n은 0 또는 1이고,R9는 수소, 또는 C1-C10알킬기이고,R3는 수소, C1-C10알킬, C3-C10시클로알킬, CF3, SR10, 1개 이상의 S, O 또는 N원자를 함유하는 5원 또는 6원 헤테로시클릭기, NR4R5, 페닐, C7-C12페닐알킬기이고, 여기에서 상기 페닐, 페닐알킬 및 헤테로시클릭기는 임의로 다른 페닐기에 융합될 수 있고, 헤테로시클릭기 및 페닐기는 임의로 C1-C6알킬, 할로겐, C1-C6할콕시, 니트로, 니트릴 CF3SR6, NR7R11또는 히드록시기에 의해 치환되며, R6, R7및 R11은 서로 동일하거나 상이한 것으로서 각각 수소 또는 C1-C10알킬기이고,R4및 R5는 서로 동일하거나 상이한 것으로서 각각 수소,C1-C10알킬 또는 페닐기이고,R10은 C1-C10알킬기이고,X1은 S 또는 0이고,D는 2-16개 원자로 된 사슬이며, 이 사슬은 기 C=X1에서 떨어진 2-6원자 위치에서 치환체를 함유하는 O 또는 S를 운반한다.
- 제1항에 있어서, X1이 0이고, D가 ZCHR-이고, R가 수소, , NH2에 의해 치환된 C1-C10알킬 또는 C1-C6알킬기이고, Z가 R2CH(COOH)NH- 또는 R1SCH2-이고, R1이 수소 또는 R8CO-이고, R8이 C1-C10알킬 또는 페닐기이고, R2가 C1-C10알킬 또는 C7-C12페닐알킬기인 화합물.
- 제2항에 있어서, Z가 R2CH(COOH)NH-이고, R3가 C1-C10알킬 또는 C3-C10시클로알킬기인 화합물.
- 제2항에 있어서, Z가 R2CH(COOH)NH-이고, Y가 S이고, R가 메릴 또는 아미노부릴기이고, n가 0이고, R2가 n-프로필 또는 페닐에틸기이고, R3가 t-부틸이고, 비대칭탄소 원자 모두가 S배열인 화합물.
- 5-t-부틸-3-[N-(1-(S)-에톡시카르보닐-3-페닐프로필)-L-알라닐]-2,3-디히드로-1,3,4-티아디아졸-2-(S)-카르복실산,5-t-부틸-3-[N2-(1-(S)-카르복시-3-페닐프로필)-L-리실]-2,3-디히드로-1,3,4-티아디아졸-2-(S)-카르복실산,5-t-부틸-3-[N-(1-(S)-에톡시카르보닐부틸-3-페닐프로필)-L-알라닐]-2,3-디히드로-1,3,4-티아디아졸-2-(S)-카르복실산 및 제약상 허용되는 그의 염들.
- 3-[N-(1-(S)-에톡시카르보닐-3-페닐프로필)-L-알라닐]-2,3-디히드로-5-페닐-1,3,4-티아디아졸-2-(S)-카르복실산,벤질 3-[N-(1-(S)-에톡시카르보닐-3-페닐프로필)-L-알라닐]-2,3-디히드로-5-페닐-1,3,4-티아디아졸-2-(R)-카르복실레이트,벤질 3-[N-(1-(S)-에톡시카르보닐-3-페닐프로필)-L-알라닐]-2,3-디히드로-5-페닐-1,3,4-티아디아졸-2-(S)-카르복실레이트,3-[N-(1-(S)-에톡시카르보닐-3-페닐프로필)-L-알라닐]-2,3-디히드로-5-페닐-1,3,4-티아디아졸-2-(R)-카르복실산,2,3-디히드로-3-(3-메르캅로-1-옥소프로필)-5-페닐-1,3,4-티아디아졸-2-카르복실실산,에틸 3-(3-아세틸티오-1-옥소프로필)-2,3-디히드로-5-페닐-1,3,4-티아디아졸-2-카르복실레이트,5-t-부틸-3-[N-(1-(S)-에톡시카르보닐-3-페닐프로필)-L-알라닐]-2,3-디히드로-1,3,4-티아디아졸-2-(S)-카르복실산벤질 5-t-부틸-3-[N-(1-(S)-에톡시카르보닐-3-페닐프로필)-L-알라닐]-2,3-디히드로-1,3,4-티아디아졸-2-(R)-카르복실레이트,벤질 5-t-부틸-3-[N-(1-(S)-에톡시카르보닐-3-페닐프로필)-L-알라닐]-2,3-디히드로-1,3,4-티아디아졸-2-(S)-카르복실레이트,5-t-부틸-3-[N2-(1-(S)-카르복시-3-페닐프로필)-L-리실]-2,3-디히드로-1,3,4-티아디아졸-2-(S)-카르복실산,벤질 3-[N6-벤질옥시카르보닐-N2-(1-(S)-벤질옥시카르보닐-3-페닐프로필)-L-리실]-5-t-부틸-2,3-디히드로-1,3,4-티아디아졸-2-(R)-카르복실레이트,벤질 -[N6-벤질옥시카르보닐-N6-(1-(S)-벤질옥시카르보닐-3-페닐프로필)-L-리실]-5-t-부틸-2,3-디히드로-1,3,4-티아디아졸-2-(S)-카르복실레이트,5-t-부틸-[N(1-(S)-에톡시카르보닐부틸)-L-알라닐]-2,3-디히드로-1,3,4-티아디아졸-2-(S)-카르복실산,벤질 5-t-부틸-[N-(1-(S)-에톡시카르보닐부틸)-L-알라닐]-2,3-디히드로-1,3,4-티아디아졸-2-(R)-카르복실레이트,벤질 5-t-부틸-[N-(1-(S)-에톡시카르보닐부틸)-L-알라닐]-2,3-디히드로-1,3,4-티아디아졸-2-(S)-카르복실레이트,3-[N-(1-(S)-에톡시카르보닐-3-페닐프로필)-L-알라닐]-2,3-디히드로-5-[4-(메틸티오)페닐]-1,3,4-티아디아졸-2-(S)-카르복실산,t-부틸 3-[N-(1-(S)-에톡시카르보닐-3-페닐프로필)-L-알라닐]-2,3-디히드로-5-[4-(메틸티오(페닐]-1,3,4-티아디아졸-2-(S)-카르복실레이트,2,3-디히드로-3-(3-메르캅로-2-(S)-메틸-1-옥소프로필)-5-페닐-1,3,4-티아디아졸-2-(S)-카르복실산,벤질 3-(3-아세틸티오-2-(S)-메틸-1-옥소프로필)-2,3-디히드로-5-페닐-1,3,4-티아디아졸-2-카르복실레이트,2-시클로헥실-5,6-디히드로-4-(3-메르캅로-1-옥소프로필)4H-1,3,4-티아디아진-5-카르복실산,벤질 4-(3-아세틸티오-1-옥소프로필)-2-시클로헥실-5,6-디히드로-4H-1,3,4-티아디아진-5-카르복실레이트,2,3-디히드로-3-(3-메르캅로-1-옥소프로필)-5-페닐-1,3,4-옥사디아졸-2-카르복실산,에틸 3(3-아세틸티오-1-옥소프로필)-2,3-디히드로-5-페닐-1,3,4-옥사디아졸-2-카르복실레이트,2,3-디히드로-3-(3-메르캅로-1-옥소프로필)-5-[4-트리플루오로메틸)페닐]-1,3,4-티아디아졸-2-카르복실산,벤질 3-(3-아세틸티오-1-옥소프로필)-2,3-디히드로-5-[4-트리플루오로메틸)페닐]1,3,4-티아디아졸-2-카르복실레이트,벤질 4-(3-아세틸티오-1-옥소프로필)-5,6-디히드로-1-메틸-2-페닐-4H-1,3,4-트리아진-5-카르복실레이트,5-t-부틸-3-[N-(1-(S)-에톡시카르보닐부틸)-L-알라닐]-2,3-디히드로-1,3,4-티아디아졸-2-(R)-카르복실산,5-t-부틸-3-[N-(1-(R)-카르보닐부틸)-L-알라닐]-2,3-디히드로-1,3,4-티아디아졸-2-(R)-카르복실산,5-t-카르복시-3-[N-(1-(R)-페닐프로필)-L-알라닐]-2,3-디히드로-1,3,4-티아디아졸-2-(S)-카르복실산,3-[N-(1-(S)-카르복시-3-페닐프로필)-L-알라닐]-2,3-디히드로-5-페닐-1,3,4-티아디아졸-2-(S)-카르복실산,5-t-부틸-3-[N-(1-(S)-카르복시-3-페닐프로필)-L-알라닐]-2,3-디히드로-1,3,4-티아디아졸-2-(S)-카르복실산,5-t-부틸-3-[N-(1-(S)-카르복실부틸)-L-알라닐]-2,3-디히드로-1,3,4-티아디아졸-2-(S)-카르복실산,5-시클로헥실-3-[N-(1-(S)-에톡시카르보닐-3-페닐프로필)-L-알라닐]-2,3-디히드로-1,3,4-티아디아졸-2-(S)-카르복실산,3-[N-(1-(S)-에톡시카르보닐-3-페닐프로필)-L-알라닐]-2,3-디히드로-5-(피리딘-3-일)-1,3,4-티아디아졸-2-(S)-카르복실산,3-[N-(1-(S)-에톡시카르보닐-3-페닐프로필)-L-알라닐]-2,3-디히드로-5-이소프로필-1,3,4-티아디아졸-2-(S)-카르복실산,5-t-부틸-3-[N2-(1-(S)-에톡시카르보닐-3-페닐프로필)-L-티실]-2,3-디히드로-1,3,4-티아디아졸-2-(S)-카르복실산,5-t-부틸-3-[N-(1-(S)-에톡시카르보닐-3-페닐프로필)-L-알라닐]-2,3-디히드로-1,3,4-티아디아졸-2-(R)-카르복실산,3-[N-(1-(S)-에톡시카르보닐-3-페닐프로필)-L-알라닐]-2,3-디히드로-5-메틸-1,3,4-티아디아졸-2-(S)-카르복실산,3-[N-(1-(S)-에톡시카르보닐-3-페닐프로필)-L-알라닐]-2,3-디히드로-5-(모르플린-4-일)-1,3,4-티아디아졸-2-(S)-카르복실산,5-t-부틸-2,3-디히드로-3-(3-메르캅로-1-옥소프로필)-1,3,4-티아디아졸-2-카르복실산,2,3-디히드로-3-(3-메르캅로-1-옥소프로필)-5-(4-메톡시페닐)-1,3,4-티아디아졸-2-카르복실산,에틸 3-(3-아세틸티오-1-옥소프로필)-2,3-디히드로-5-메틸아미노-1,3,4-티아디아졸-2-카르복실레이트,2,3-디히드로-3-(3-메르캅로-1-옥소프로필)-5-(2-메틸페닐)-1,3,4-티아디아졸-2-카르복실산,5-(푸탄-2-일)-2,3-디히드로-3-(3-메르캅로-1-옥소프로필)-1,3,4-티아디아졸-2-카르복실산,에틸 3-(3-아세틸티오-1-옥소프로필)-5-(4-클로로페닐)-2,3-디히드로-1,3,4-티아디아졸-2-카르복실레이트,벤질 3-(3-아세틸티오-1-옥소프로필)-5-벤질-2,3-디히드로-1,3,4-티아디아졸-2-카르복실레이트,벤질 3-(3-아세틸티오-1-옥소프로필)-2,3-디히드로-5-(2-페닐에틸)-1,3,4-티아디아졸-2-카르복실레이트,에틸 3-(3-아세틸티오-1-옥소프로필)-2,3-디히드로-5-(나프탈렌-2-일)-1,3,4-티아디아졸-2-카르복실레이트,5-(아다만트-1-일)-2,3-디히드로-3-(3-메르캅로-1-옥소프로필)-1,3,4-티아디아졸-2-카르복실산,에틸 5-(아다만트-1-일)-2,3-디히드로-3-(3-메르캅로-1-옥소프로필)-1,3,4-티아디아졸-2-카르복실레이트,2,3-디히드로-3-(3-메르캅로-1-옥소프로필)-5-메틸-1,3,4-티아디아졸-2-카르복실산,5-시클로헥실-2,3-디히드로-3-(3-메르캅로-1-옥소프로필)-1,3,4-티아디아졸-2-카르복실산,2,3-디히드로-3-(3-메르캅로-1-옥소프로필)-5-메틸티오-1,3,4-티아디아졸-2-카르복실산 및 벤질 3-[N-(1-(S)-에톡시카르보닐-3-페닐프로필)-L-알라닐]-2,3-디히드로-5-메틸티오-1,3,4-티아디아졸-2-(S)-카르복실레이트 및 제약상 허용되는 그의 염들.
- 고혈압 증상을 치료하기 위한 약제의 제조에 있어서, 제1항에서 정의한 바와 같은 일반식(I)의 화합물의 용도.
- a) 1개 이상의 아미노산 또는 카르복실산기가 보호된 제1항에서 정의한 일반식(I)의 화합물로부터 보호기를 제거하고,b) 일반식(Ⅱ)(여기에서, R3, Y 및 n은 1항에서 정의한 바와 같음)의 화합물 또는 그의 염, 에스테르, 아미드, 호변이 성질체, 또는 보호된 유도체를 일반식(Ⅲ)(여기에서, D및 X1은 1항에서 정의한 바와 같으며, X는 양호한 이탈기임)의 화합물과 반응시키고,c) 헤테로시클릭 고리를 함유하는 Y의 비대칭 탄소 원자가 R배열인 제1항에서 정의한 바와 같은 일반식(I)의 화합물을 탄소 원자가 S배열인 대응하는 화합물로 전환시키고,d) 일반식(Ⅱ)의 화합물(여기에서, R3, Y 및 n은 1항에서 정의한 바와 같음)을 일반식(Ⅵ)(여기에서, D및 X1은 1항에서 정의한 바와 같음)의 화합물과 반응시키고,e) 제1항에서 정의한 바와 같은 일반식(I)의 화합물 또는 그의 또다른 염, 에스테르 또는 아미드를, 이용할 수 있는 제약상 허용되는 이온을 함유하고, 일반식(I)의 화합물 또는 그의 다른 염, 에스테르 또는 아미드를 상기 일반식(I)의 화합물의 제약상 허용되는 염으로 전환시킬 수 있는 화합물로 처리해서 상기 일반식(I)의 화합물의 제약상 허용되는 염을 제조하며, 필요한 경우, 생성된 화합물로부터 보호기를 제거하거나 또는 일반식(I)의 화합물을 제약상 허용되는 그의 염, 에스테르 또는 아미드로 전환시키거나, 또는 이와 반대로 전환시킴을 특징으로 하는 제1항에서 정의한 바와 같은 일반식(I)의 화합물 또는 제약상 허용되는 그의 염, 에스테르, 또는 아미드의 제조방법.
- 일반식(Ⅱ)화합물과 그의 염, 에스테르, 아미드 및 호변이성 질체.상기 식중 Y는 S,O 또는 NR9이고, n은 0 또는 1이고,R9은 수소, 또는 C1-C10알킬기이고,R3는 수소, C1-C10알킬, C3-C10시클로알킬, CF3, SR10, 1개 이상의 S,O 또는 N원자를 함유하는 5원 또는 6원 헤테로시클릭기, NR4R5, 페닐, C7-C12페닐알킬기이고, 여기에서 상기 페닐, 페닐알킬 및 헤테로시클릭기는 임의로 다른 페닐기에 융합될 수 있고, 헤테로시클릭기 및 페닐기는 임의로 C1-C6알킬, 할로겐, C1-C6알콕시, 니트로, 니트릴 CF3SR6, NR7R11또는 히드록시기에 의해 치환되며, R6, R7및 R11은 서로 동일하거나 상이한 것으로서, 각각 수소 또는 C1-C10알킬기이고,R4및 R5는 서로 동일하거나 상이한 것으로서 각각 수소,C1-C10알킬 또는 페닐기이고,R10은 C1-C10알킬기이다.
- 제1항에 있어서 약제로 사용하기 위한 화합물.
- 제약상 허용되는 희석제, 부형제 또는 담체와의 혼합한 제1항에 의한 화합물로 되는 약제.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB858521697A GB8521697D0 (en) | 1985-08-31 | 1985-08-31 | Nitrogen & sulphur heterocycles |
GB85/21697 | 1985-08-31 | ||
GB858524932A GB8524932D0 (en) | 1985-10-09 | 1985-10-09 | Nitrogen & sulphur heterocycles |
GB85/24932 | 1985-10-09 | ||
GB85/30143 | 1985-12-06 | ||
GB858530143A GB8530143D0 (en) | 1985-12-06 | 1985-12-06 | Nitrogen |
GB868609793A GB8609793D0 (en) | 1986-04-22 | 1986-04-22 | Nitrogen containing heterocycles |
GB86/09793 | 1986-04-22 | ||
GB868612060A GB8612060D0 (en) | 1986-05-17 | 1986-05-17 | Nitrogen containing heterocycles |
GB86/12060 | 1986-05-17 | ||
SU874202059A RU1804458C (ru) | 1985-08-31 | 1987-02-09 | Способ получени производных 1,3,4-тиадиазол-2-карбоновых кислот или их фармацевтически приемлемых солей, сложных эфиров или амидов |
Publications (2)
Publication Number | Publication Date |
---|---|
KR870002107A true KR870002107A (ko) | 1987-03-30 |
KR940009528B1 KR940009528B1 (ko) | 1994-10-14 |
Family
ID=27546912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019860007234A KR940009528B1 (ko) | 1985-08-31 | 1986-08-30 | 헤테로 고리 화합물의 제조 방법 |
Country Status (19)
Country | Link |
---|---|
US (1) | US4927822A (ko) |
EP (1) | EP0217519B1 (ko) |
JP (1) | JPH0788365B2 (ko) |
KR (1) | KR940009528B1 (ko) |
AT (1) | ATE72431T1 (ko) |
AU (1) | AU591165B2 (ko) |
BE (1) | BE905351A (ko) |
CA (1) | CA1305286C (ko) |
CH (1) | CH671397A5 (ko) |
DK (1) | DK406386A (ko) |
FI (1) | FI87205C (ko) |
FR (1) | FR2586679B1 (ko) |
GR (1) | GR862234B (ko) |
IE (1) | IE59432B1 (ko) |
IL (1) | IL79841A (ko) |
LU (1) | LU86569A1 (ko) |
NO (1) | NO166180C (ko) |
NZ (1) | NZ217398A (ko) |
PT (1) | PT83277B (ko) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT87616B (pt) * | 1987-06-24 | 1992-09-30 | Smithkline Beecham Corp | Processo de preparacao de antagonistas do leucotrieno e de composicoes farmaceuticas |
GB8825541D0 (en) * | 1988-11-01 | 1988-12-07 | Fisons Plc | Formulation |
WO1994020460A1 (en) * | 1993-03-11 | 1994-09-15 | Smithkline Beecham Corporation | Chemical compounds |
EP1454903B9 (en) | 2001-12-11 | 2011-10-05 | Kyowa Hakko Kirin Co., Ltd. | Thiadiazoline derivatives for treating cancer |
ES2377498T3 (es) | 2003-04-18 | 2012-03-28 | Kyowa Hakko Kirin Co., Ltd. | Inhibidor de quinesina en etapa M |
JPWO2004111023A1 (ja) * | 2003-06-10 | 2006-07-27 | 協和醗酵工業株式会社 | チアジアゾリン−1−オキシド誘導体 |
KR20060014071A (ko) * | 2003-06-10 | 2006-02-14 | 교와 핫꼬 고교 가부시끼가이샤 | 티아디아졸린 유도체 |
WO2005035512A1 (ja) * | 2003-10-10 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | チアジアゾリン誘導体 |
US7449486B2 (en) * | 2004-10-19 | 2008-11-11 | Array Biopharma Inc. | Mitotic kinesin inhibitors and methods of use thereof |
EP1870404A4 (en) * | 2005-03-22 | 2010-07-14 | Kyowa Hakko Kirin Co Ltd | MEANS FOR THE TREATMENT OF A HEMATOPOIETIC TUMOR |
KR20070113300A (ko) * | 2005-03-22 | 2007-11-28 | 교와 핫꼬 고교 가부시끼가이샤 | 고형종양 치료제 |
UA95907C2 (en) | 2005-05-02 | 2011-09-26 | Эррей Биофарма Инк. | Mitotic kinesin inhibitors and methods of use thereof |
EP1908755A4 (en) | 2005-06-24 | 2009-06-24 | Kyowa Hakko Kirin Co Ltd | THERAPEUTIC AGENT AGAINST RESTENOSIS |
DE102006002065B4 (de) * | 2006-01-16 | 2007-11-29 | Infineon Technologies Austria Ag | Kompensationsbauelement mit reduziertem und einstellbarem Einschaltwiderstand |
AU2007288338B2 (en) | 2006-08-21 | 2012-05-03 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
JP2010505870A (ja) * | 2006-10-03 | 2010-02-25 | アレイ バイオファーマ、インコーポレイテッド | 有糸分裂キネシン阻害剤としてのオキサジアゾール誘導体およびチアジアゾール誘導体、ならびにそれらの使用方法 |
TW200940050A (en) * | 2007-11-28 | 2009-10-01 | Synta Pharmaceuticals Corp | Polymorphs of N-malonyl-bis(N'-methyl-N'-thiobenzoylhydrazide) |
EP2225201A2 (en) * | 2007-11-28 | 2010-09-08 | Synta Pharmaceuticals Corp. | Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4091024A (en) | 1976-12-03 | 1978-05-23 | E. R. Squibb & Sons, Inc. | Pyrrolidine and piperidine-2-carboxylic acid derivatives |
US4198517A (en) * | 1976-12-03 | 1980-04-15 | E. R. Squibb & Sons, Inc. | Histidine derivatives |
IL58849A (en) | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
US4254267A (en) * | 1979-10-25 | 1981-03-03 | E. R. Squibb & Sons, Inc. | Mercaptoacyldihydropyrazole carboxylic acid derivatives |
US4312990A (en) * | 1980-09-11 | 1982-01-26 | E. R. Squibb & Sons, Inc. | 1-Mercaptoacyl-3-[(aminosulfonyl) phenyl]-4,5-dihydro-1H-pyrazole-5-carboxylic acid |
EP0048159A3 (en) * | 1980-09-17 | 1982-05-12 | University Of Miami | Novel carboxyalkyl peptides and thioethers and ethers of peptides as antihypertensive agents |
-
1986
- 1986-08-15 AT AT86306325T patent/ATE72431T1/de not_active IP Right Cessation
- 1986-08-15 EP EP86306325A patent/EP0217519B1/en not_active Expired - Lifetime
- 1986-08-25 AU AU61798/86A patent/AU591165B2/en not_active Ceased
- 1986-08-26 CH CH3427/86A patent/CH671397A5/fr not_active IP Right Cessation
- 1986-08-26 DK DK406386A patent/DK406386A/da not_active Application Discontinuation
- 1986-08-26 IL IL79841A patent/IL79841A/xx not_active IP Right Cessation
- 1986-08-27 US US06/901,048 patent/US4927822A/en not_active Expired - Fee Related
- 1986-08-28 NO NO863457A patent/NO166180C/no unknown
- 1986-08-28 FI FI863488A patent/FI87205C/fi not_active IP Right Cessation
- 1986-08-29 CA CA000517181A patent/CA1305286C/en not_active Expired - Fee Related
- 1986-08-29 GR GR862234A patent/GR862234B/el unknown
- 1986-08-29 PT PT83277A patent/PT83277B/pt not_active IP Right Cessation
- 1986-08-29 BE BE0/217101A patent/BE905351A/fr not_active IP Right Cessation
- 1986-08-29 LU LU86569A patent/LU86569A1/fr unknown
- 1986-08-29 JP JP61201875A patent/JPH0788365B2/ja not_active Expired - Lifetime
- 1986-08-29 FR FR8612233A patent/FR2586679B1/fr not_active Expired
- 1986-08-29 NZ NZ217398A patent/NZ217398A/xx unknown
- 1986-08-29 IE IE232286A patent/IE59432B1/en not_active IP Right Cessation
- 1986-08-30 KR KR1019860007234A patent/KR940009528B1/ko not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DK406386D0 (da) | 1986-08-26 |
BE905351A (fr) | 1987-03-02 |
IE862322L (en) | 1987-02-28 |
CA1305286C (en) | 1992-07-14 |
NO166180B (no) | 1991-03-04 |
FR2586679B1 (fr) | 1988-12-30 |
PT83277B (pt) | 1989-03-30 |
AU6179886A (en) | 1987-03-05 |
NO863457L (no) | 1987-03-02 |
FI87205B (fi) | 1992-08-31 |
EP0217519B1 (en) | 1992-02-05 |
DK406386A (da) | 1987-03-01 |
JPS6253976A (ja) | 1987-03-09 |
FI863488A (fi) | 1987-03-01 |
NO166180C (no) | 1991-06-19 |
LU86569A1 (fr) | 1986-12-02 |
NO863457D0 (no) | 1986-08-28 |
FI863488A0 (fi) | 1986-08-28 |
JPH0788365B2 (ja) | 1995-09-27 |
EP0217519A1 (en) | 1987-04-08 |
KR940009528B1 (ko) | 1994-10-14 |
US4927822A (en) | 1990-05-22 |
NZ217398A (en) | 1989-04-26 |
FR2586679A1 (fr) | 1987-03-06 |
ATE72431T1 (de) | 1992-02-15 |
FI87205C (fi) | 1992-12-10 |
CH671397A5 (ko) | 1989-08-31 |
IL79841A0 (en) | 1986-11-30 |
PT83277A (en) | 1986-09-01 |
IE59432B1 (en) | 1994-02-23 |
AU591165B2 (en) | 1989-11-30 |
GR862234B (en) | 1986-12-31 |
IL79841A (en) | 1992-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR870002107A (ko) | 신규 화합물, 그 제조 방법 및 이 화합물을 함유하는 조성물 | |
RU2217436C2 (ru) | Производные оксадиазола, тиадиазола или триазола, являющиеся ингибиторами сериновых протеаз, и содержащие их фармацевтические композиции | |
KR100802369B1 (ko) | 글루코겐 포스포릴라제 억제제로서의 비시클릭 피롤릴아미드 | |
RU2005121667A (ru) | 5-замещенные пиразиновые или пиридиновые активаторы глюкокиназы | |
KR940021063A (ko) | 퀴놀론카르복실산 유도체, 이의 제조방법 및 용도 | |
RU96111018A (ru) | Амиды терапевтического назначения | |
KR890005095A (ko) | 신규 화합물들 | |
RU2000104850A (ru) | Карбамилокси соединения, ингибирующие опосредованную vla-4 адгезию лейкоцитов | |
RU2006125761A (ru) | Новые производные оксазолидинона | |
TW200932221A (en) | Imidazole carbonyl compounds | |
KR890002209A (ko) | 메틸렌 포스포노알킬포스피네네이트, 이를 함유하는 약학적 조성물, 및 비정상적 칼슘 및 인산염 대사를 치료하는 방법 | |
KR910016724A (ko) | 소염제로서의 2-치환 티아졸리디논, 옥사졸리디논 및 이미다졸리디논의 3,5-디-t-부틸-4-히드록시페닐메틸렌 유도체 | |
JP2009501216A5 (ko) | ||
RU2007144612A (ru) | Ингибиторы митотического кинезина и способы их применения | |
RU99101864A (ru) | Новое производное тиофена и содержащая его фармацевтическая композиция | |
RU2008110961A (ru) | (индол-3-ил)-гетероциклические производные в качестве агонистов каннабиноидных св1 рецепторов | |
CA2377527A1 (en) | Heteroaromatic ring compounds | |
AU729341B2 (en) | Hydantoin derivatives having an inhibitory activity for farnesyl transferase | |
KR880007461A (ko) | 헤테로 사이클-치환 디포스포네이트화합물 및 이의 약제학적 조성물 | |
KR850008489A (ko) | 세팔로스포린 유도체의 제법 | |
KR910000614A (ko) | 신규 화합물 | |
KR970701705A (ko) | 5-HT₃ 수용체 효능제, 신규한 티아졸 유도체 및 이의 중간체(5-HT₃receptor agonist, novel thiazole derivative, and intermediate therefor) | |
HUT40118A (en) | Process for preparing 5-/azolyl-oxy-phenyl-carbamoyl/-barbituric acid-derivatives | |
RU2002102248A (ru) | Дигидробензодиазепины и их применение при лечении дислипидаемии | |
KR910000684A (ko) | 소염제 페나메이트 1,3,4-티아디아졸 및 1,3,4-옥사디아졸 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
LAPS | Lapse due to unpaid annual fee |